A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Involvement in the planning and/or conduct of the study

Previous treatment with a DDR agent

Participation in another clinical study with an investigational product during the last 21 days or 5 half-lives of the investigational product, whichever is longer

Receiving, or having received during the week prior to first dose, corticosteroids at a dose \> 10 mg prednisone/day or equivalent for any reason

Known hypersensitivity or contraindication to any of the investigational agents or their excipients

Small molecule investigational medicinal products (IMPs) within 28 days prior to first dose; biological IMP within 42 days prior to first dose

Receiving, or received, concomitant medications, herbal supplements and/or foods that significantly modulate Cytochrome P450 3A4 (CYP3A4) inhibitors or moderate Cytochrome P450, family 3, subfamily A (CYP3A) inhibitors, strong CYP3A inducers or moderate CYP3A inducers

Impaired hepatic or renal function,inadequate bone marrow reserve or organ function

Cardiac dysfunction defined as: Myocardial infarction within six months of study entry, New York Heart Association (NYHA) Class II/III/IV heart failure, unstable angina, unstable cardiac arrhythmias or reduced LVEF \< 55%

Any of the following cardiac criteria: Mean resting corrected QTc interval using the Fridericia formula (QTcF) greater than 450 msec/male and greater than 470 msec/female or congenital long QT syndrome, clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiography (ECG), factors that increase the risk of QTc prolongation or risk of arrhythmic events, patients at risk of brain perfusion problems, relative hypotension (\<100/60 mm Hg) or clinically relevant orthostatic hypotension (\>20 mm Hg), uncontrolled hypertension

Any other malignancy (i.e., non-HNSCC) which has been active or treated within the past three years (except cervical intra-epithelial neoplasia and non-melanoma skin cancer)

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection

Judgement by the Investigator that the patient should not participate in the study

Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML

Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)

Non-leukocyte depleted whole blood transfusion within 120 days of the date of patient's start on the study

What this study is about